Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-09-25
2007-09-25
Harris, Alana M. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S300000, C530S350000, C530S385000, C530S386000, C530S387300, C530S387700, C530S388100, C530S385000, C424S130100, C424S133100, C424S134100, C424S135100, C424S138100, C424S139100, C424S141100, C424S142100, C424S143100
Reexamination Certificate
active
09194356
ABSTRACT:
A specific binding member is specific for and binds directly to the ED—B oncofoetal domain of fibronectin (FN).
REFERENCES:
patent: 4894326 (1990-01-01), Matsuura et al.
patent: 5177015 (1993-01-01), Matsuura et al.
patent: 5243029 (1993-09-01), Matusuura et al.
patent: 5523229 (1996-06-01), Feinberg et al.
patent: 5648485 (1997-07-01), Dolphin et al.
patent: 5710134 (1998-01-01), Bosslet et al.
patent: 5734025 (1998-03-01), Komai et al.
patent: 5747452 (1998-05-01), Ruoslahti et al.
patent: 5817776 (1998-10-01), Goodman et al.
patent: 5831088 (1998-11-01), Dolphin et al.
patent: 5837813 (1998-11-01), Ruoslahti et al.
patent: 5843156 (1998-12-01), Slepian et al.
patent: 5849701 (1998-12-01), Roberts et al.
patent: 5877289 (1999-03-01), Thorpe et al.
patent: 5913884 (1999-06-01), Trauner et al.
patent: 5976535 (1999-11-01), Fritzberg et al.
patent: 6004555 (1999-12-01), Thorpe et al.
patent: 6015897 (2000-01-01), Theodore et al.
patent: 6036955 (2000-03-01), Thorpe et al.
patent: 6051230 (2000-04-01), Thorpe et al.
patent: 6093399 (2000-07-01), Thorpe et al.
patent: 6140470 (2000-10-01), Garen et al.
patent: 6267722 (2001-07-01), Anderson et al.
patent: 6394952 (2002-05-01), Anderson et al.
patent: 6696245 (2004-02-01), Winter et al.
patent: 6749853 (2004-06-01), Thorpe et al.
patent: 2004/0001790 (2004-01-01), Hilger et al.
patent: 2004/0013640 (2004-01-01), Zardi et al.
patent: 0125023 (1984-11-01), None
patent: 184187 (1986-06-01), None
patent: 0211047 (1987-02-01), None
patent: 239400 (1987-09-01), None
patent: 0 344 134 (1989-11-01), None
patent: 0344134 (1989-11-01), None
patent: 0371998 (1990-06-01), None
patent: 0396612 (1990-11-01), None
patent: 0550400 (1993-07-01), None
patent: 0120694 (1994-10-01), None
patent: 0731167 (1996-09-01), None
patent: 0760679 (1997-03-01), None
patent: 2188638 (1987-10-01), None
patent: 0276598 (1990-03-01), None
patent: 4169195 (1992-06-01), None
patent: WO 93/11161 (1993-06-01), None
patent: WO 94/13804 (1994-06-01), None
patent: WO 96/23816 (1996-08-01), None
patent: WO 9745544 (1997-12-01), None
patent: WO 9958570 (1999-10-01), None
patent: WO 0162800 (2001-08-01), None
Bird et al. Single-chain antigen binding proteins. Science 242:423-426, Oct. 21, 1988.
Clackson et al. Making antibody fragments using phage display libraries. Nature 352: 624-628, Aug. 15, 1991.
J. Peters et al.: “Expression of the alternatively spliced EIIIB segment of fibronectin.” Cell Adhesion and Communication, vol. 3, No. 1, 1995, USA, pp. 67-89, XP002042097 cited in the application.
D. Zang et al.: “Antibody specific for extra domain B of fibronectin demonstrates elevated levels of both extra domain B(+) and B(−) fibronectin in osteoarthritic canine cartilage.” Matrix Biology, vol. 14, No. 8, Oct. 1995, Stuttgart, Germany, pp. 623-633, XP002042098.
DATABASE WPI Week 9017 Derwent Publications Ltd., London, GB; AN 90-128252 XP002042103 & JP 02 076 598 A (Fujita Gakuen et al.) , Mar. 15, 1990.
DATABASE WPI Week 9231 Derwent Publications Ltd., London, GB; AN 92-253398 XP002042104 & JP 04 169 195 A (Fujita Gakuen et al.) , Jun. 17, 1992.
P. Castellani et al.: “The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis.” International Journal of Cancer, vol. 59, No. 5 Dec. 5, 1994, New York, NY, USA, pp. 612-618, XP002042099 cited in the application.
L. Zardi et al.: “Transformed human cells produce a new fibronectin isoform by a preferential alternative splicing of a previously unobserved exon.” The EMBO Journal, vol. 6, No. 8, Aug. 1987, Cambridge, GB, pp. 2337-2342, XP002042100 cited in the application.
B. Carnemolla et al.: “The inclusion of the type III repeat ED-B in the fibronectin molecule genetrates conformational modifications that unmask a cryptic sequence.” The Journal of Biological Chemistry, vol. 267, No. 34, Dec. 5, 1992, Baltimore, MD, USA, pp. 24689-24692, XP002042101 cited in the application.
B. Carnemolla et al.: “Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain.” International Journal of Cancer, vol. 68, No. 3, Nov. 4, 1996, New York, NY, USA, pp. 397-405, XP002042102.
Dario Neri et al., “High-affinity Antigen Binding by Chelating Recombinant Antibodies (CRAbs),” J. Mol. Biol. (1995) 246, 367-373.
Ashley Publications Ltd., ISSN 1354-3776, “Antibodies to the ED-B domain of fibronectin, their constructs and uses,” Exp. Opin. Ther. Patents (1998) 8(7):907-910.
Fredrik Nilsson et al., “The use of phage display for the development of tumor targeting agents,” Advanced Drug Delivery Reviews 43 (2000) 165-196.
Matsuura et al., “The oncofetal domain of fibronectin defined by monoclonal antibody FDC-6: Its presence in fibronectins from fetal and tumor tissues and its absence in those from normal adult tissues and plasma,” Proc.Natl.Acad.Sci., vol. 82, pp. 6517-6521, Oct. 1985.
Matsuura et al., “An α-N-Acetylgalactosaminylation at the Threonine Residue of a Defined Peptide Sequence Creates the Oncofetal Peptide Epitope in Human Fibronectin,” The Journal of Biological Chemistry, vol. 264, No. 18, pp. 10472-10476, 1989.
Matsuura et al., “The Oncofetal Structure of Human Fibronectin Defined by Monoclonal Antibody FDC-6,” The Journal of Biological Chemistry, vol. 263, No. 7, pp. 3314-3322, 1988.
Isemura et al., “Isolation and Charaterization of Human Placenta Fibronectin,” J.Biochem. 96, 163-169, 1984.
Epstein, Jay S., “FDA Regulation of HIV-Related Tests and Procedure,” Aids Testing: A comprehensive Guide to Technical, Medical, Social, Legal, and Management Issues, Eds. Schochetman and George, pp. 52-61, Spinger-Verlag, New York, 1994.
Korver et al., “Measurement of Primary In Vivo IgM- and IgG-Antibody Response to KLH in Humans: Implications of Pre-Immune IgM Binding in Antigen-Specific ELISA,” Journal of Immunological Methods, 1984, pp. 241-251, vol. 74.
Weir, C. et al., “An Immunoglobulin G1 Monoclonal Antibody Highly Specific to the Wall ofCryptosporidiumOocysts,” Clinical and Diagnostic Laboratory Immunology, Sep. 2000, p. 745-750, vol. 7, No. 5.
Nozawa, Shiro, et al., “HMMC-1: A Humanized Monoclonal Antibody With Therapeutic Potential Against Müllerian Duct-Related Carcinomas,” Clinical Cancer Research, Oct. 15, 2004, pp. 7071-7078, vol. 10.
23 slide, power-point of Dr. Zardi (Feb. 2007).
Alan L. Epstein, et al.; Identification of a Monoclonal Antibody, TV-1, Directed against the Basement Membrane of Tumor Vessels, and Its Use to Enhance the Delivery of Macromolecules to Tumors after Conjugation with Interleukin 2′; Cancer Research 55, 2673-2680, Jun. 15, 1995.
Tomohiko Fukuda et al., “Mice lacking the EDB segment of fibronectin develop normally but exhibit reduced cell growth and fibronectin matrix assembly in vitro,” Cancer Research, Oct. 1, 2002, pp. 5603-5610, vol. 62.
Andrew Griffiths et al., “Isolation of high affinity human antibodies directly from large synthetic repertoires,” The EMBO Journal, 1994, pp. 3245-3260, vol. 13, No. 14.
Dario Neri et al., “Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin Isoform”, Nature Biotechnology, vol. 15, Nov. 1997, pp. 1271-1275.
Dario Neri et al., “Affinity reagents against tumor-associated extracellular molecules and newforming vessels,” Advanced Drug Delivery Reviews, Apr. 6. 1998, pp. 43-52, vol. 31, No. 1-2, XP002124780, pp. 46, right-hand column, p. 49, left-hand column.
Pini, A., et al., “Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel,” Journal of Biological Chemistry, Aug. 21, 1998, pp. 21769-21776, vol. 273, No. 34, XP002124781.
Viti F. et al., “Increased Binding Affinity and Valence of Recombinant Antibody F
Carnemolla Barbara
Neri Dario
Winter Gregory Paul
Zardi Luciano
Harris Alana M.
Millen White Zelano & Branigan P.C.
Philogen S.p.A.
LandOfFree
Antibodies to the ED-B domain of fibronectin, their... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies to the ED-B domain of fibronectin, their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to the ED-B domain of fibronectin, their... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3734221